Probiotics for Digestive Health

Engineered gut bacteria that can consume carbohydrates and synthesize fiber to improve gut health. The bacteria are modified to express a fiber-synthesizing enzyme that uses carbohydrates to produce fiber in the gut. Administering these bacteria can decrease carbohydrate levels and increase fiber levels in the gut. This aims to counteract the negative effects of excessive carbohydrate consumption and insufficient fiber intake on gut microbiome composition and health.

Source

Composition of bacteria that can be used as therapeutic probiotics to treat conditions related to chronic inflammation of the gastrointestinal tract like IBD. The composition includes strains like Akkermansia species, Bacteroides uniformis, Bacteroides xylanisolvens, Clostridium butyricum, Clostridium scindens, Clostridium symbiosum, Eubacterium callanderi, Extibacter species, and Intestinimonas butyriciproducens. These strains have been identified in healthy human gut microbiomes and have properties like producing short-chain fatty acids and indole metabolites that can help restore gut homeostasis and reduce inflammation.

Source

Lactic acid bacteria strain Lactiplantibacillus plantarum KM2 isolated from aged meat that exhibits proteolytic activity, immunity enhancement, and probiotic properties. The strain has potential applications as an ingredient in probiotics, functional foods, and pharmaceuticals.

Source

Lactobacillus strain IMAU80584 that has potential probiotic uses for fermentation of dairy products and inhibiting pathogenic bacteria. It has acid-producing abilities, acid tolerance, and ability to grow over a wide range of temperature and pH conditions. The strain can be used as a fermentation agent for making fermented milk products like soy or cow milk. It can also be used as a supplement to prevent and treat pathogenic bacterial infections.

Source

Preventing and treating intestinal microbiome aberrations in Cesarean section-born infants to improve their health and prevent disorders. The method involves administering a composition containing specific bacterial species to CS-born infants to correct their microbiome. The composition comprises at least one Bacteroides species (e.g., Bacteroides vulgatus) and/or at least one Bifidobacterium species (e.g., Bifidobacterium longum). This can be given soon after birth to mimic the natural maternal transmission of bacteria during vaginal birth.

Source

Probiotic strain Lactobacillus paracasei 207-27 isolated from infant intestines. The strain has high survivability against gastric acid and bile salts, good adhesion to intestinal mucosa, and can activate immune cells to secrete anti-inflammatory cytokines like IL-10. Administering this strain can inhibit inflammation, improve immunity, and alleviate allergies.

Source

Strains of the bacteria Parabacteroides distasonis for use in the treatment and prevention of gastrointestinal diseases, such as inflammatory bowel diseases, and disorders associated with gastrointestinal diseases. The strains can be administered in live or inactivated forms. The strains are selected from specific Parabacteroides distasonis strains that have been deposited.

Source

Solid enterically-coated dosage forms of bacteria or bacterial extracellular vesicles that can be orally administered to modulate immune and physiological effects in the body. The enteric coating allows release in the small intestine where the bacteria can interact with immune and epithelial cells. This targeted delivery to the small intestine enhances the effectiveness compared to non-enterically coated forms. The dosage forms can contain isolated bacterial extracellular vesicles, bacteria, or both.

Source

Soft, chewable gummies or tablets containing kombucha tea powder. The formulation combines bacterial and yeast treated tea powder with a biopolymer like pectin and sugar to make a gummy matrix. The gummies can also contain other ingredients like vitamins, minerals, probiotics, flavorings, and colors.

Source

Reactivating lyophilized probiotics to confer a proper negative zeta-potential on the cell surface of the probiotics. The composition includes amino acids like L-lysine or L-tyrosine that reactivate lyophilized probiotics and improve their functionality by conferring a suitable negative zeta potential on the cell surface of the lyophilized probiotics. This improves intestinal survivability and adhesion by reactivating lyophilized probiotics and conferring a proper negative zeta-potential on them.

Source

A strain of Pediococcus acidilactici bacteria called TAK 589 Coccobest that can be used as a probiotic additive in food and beverages to improve gut health. The strain has antimicrobial and antioxidative properties that help stabilize the gastrointestinal microbiota and prevent infections. It can be used as a probiotic for humans and animals, as well as a starter culture for fermenting plant matter. The strain is resistant to antibiotics and does not suppress beneficial lactobacilli.

Source

Probiotic tablets and powders containing isomaltulose as the excipient. The use of isomaltulose as a replacement for conventional excipients like isomalt in probiotic products that improves viability, stability, and dental health. The tablets and powders are made by mixing probiotic bacteria with isomaltulose and compressing or packaging the mixture.

Source

A strain of Lactobacillus rhamnosus, designated CMU-pb-7, isolated from human feces. The strain exhibits probiotic properties and can be used in various applications such as dietary supplements, functional foods, and pharmaceuticals. The strain has potential to be developed into antioxidant drugs to treat or prevent diseases associated with oxidative stress.

Source

A method for producing encapsulated probiotics with improved stability and viability, as well as a method of treating disease using the encapsulated probiotics. The method involves culturing probiotics in a medium containing alginate and a salt that forms a hydrogel. The acid produced by the probiotics dissociates the cation from the salt, allowing the alginate to spontaneously form a hydrogel entrapping the probiotics. The encapsulated probiotics are then recovered. This simple method provides encapsulated probiotics that have improved freeze-drying viability, heat tolerance, and shelf stability compared to conventional encapsulation techniques.

Source

Strain of the gut bacteria Akkermansia muciniphila, identified as AK32. The strain can be used to develop pharmaceuticals, probiotics, functional foods and supplements for preventing or treating intestinal damage and improving gut health. The strain produces a unique enzyme that may contribute to its beneficial effects.

Source

A defined bacterial cocktail for treating gastrointestinal disorders like Clostridioides difficile infections (CDI) that provides an alternative to fecal microbiota transplantation (FMT). The cocktail is a Live Biotherapeutic Product (LBP) comprising carefully selected, purified, and cultured bacterial strains isolated from healthy donors. These strains can be precisely detected and quantified in recipients using computationally enabled strain tracking. This allows monitoring of engraftment, efficacy, and long-term stability of the donor strains. The LBP provides a defined, effective, and trackable bacterial treatment for gut disorders.

Source

Using Adlercreutzia bacterial strains for treating inflammatory diseases like non-alcoholic fatty liver disease (NAFLD) and inflammatory bowel diseases (IBD). The Adlercreutzia strains, such as Adlercreutzia equolifaciens, exhibit anti-inflammatory effects and can reduce symptoms like weight gain, hyperglycemia, and liver inflammation in disease models.

Source

Use of lactic acid bacteria or fermented products to maintain or improve gastrointestinal health by reducing Helicobacter pylori infection which can cause gastric issues. The lactic acid bacteria strains Lactobacillus paracasei ET-66, Lactobacillus salivarius subsp. salicinius AP-32, and Lactobacillus plantarum LPL28 were found to adhere to gastric cells, inhibit H. pylori growth and urease activity, and agglutinate H. pylori. Administering compositions containing these strains or their fermentation products provides a natural and safe way to improve gastrointestinal health.

Source

Lactic acid bacteria composition containing lactic acid bacteria (Lactobacillus paracasei) and amino acids (lysine, arginine, and glutamate) as active ingredients to protect the bacteria from gastric acid and bile conditions. The amino acids enhance expression of the gadC gene in the bacteria, which helps them survive acidic environments. The composition can be used in probiotics, functional foods, etc.

Source

Novel Lactobacillus reuteri strain that promotes intestinal development and maturation. The strain, called Lactobacillus reuteri DS0384, can be used in products like probiotics, fermented foods, pharmaceuticals, health foods, and animal feed to enhance intestinal health and prevent/treat disorders like inflammatory bowel disease.

Source